
---
title: OHA (Oral Hypoglycemic Agents) - INICET Cheatsheet
markmap:
  colorFreezeLevel: 6
---

## OHA - Quick Revision

### Biguanides
- **Metformin**
  - MoA: ↓ Hepatic Glucose Production, ↑ Peripheral Insulin Sensitivity
  - Side Effects: GI Upset, B12 Deficiency, Lactic Acidosis (Rare, but key)
  - Contraindications: Renal Failure (eGFR <30), Hepatic Impairment, Heart Failure (Severe), Contrast use (hold)
  - Pearls: First-line, Weight Neutral/Loss, No Hypoglycemia Risk

### Insulin Secretagogues
- **Sulfonylureas (Glibenclamide, Glipizide, Gliclazide, Glimepiride)**
  - MoA: Stimulate Insulin Secretion (β-cell K+ channel)
  - Side Effects: Hypoglycemia (Key), Weight Gain
  - Contraindications: Severe Renal/Hepatic Impairment
  - Pearls: High Hypoglycemia Risk (especially 1st gen), Cheap

- **Meglitinides (Repaglinide, Nateglinide)**
  - MoA: Stimulate Insulin Secretion (faster, shorter action than SUs)
  - Side Effects: Hypoglycemia, Weight Gain (less than SUs)
  - Pearls: Post-prandial glucose control, take before meals

### Insulin Sensitizers
- **Thiazolidinediones (TZDs) (Pioglitazone, Rosiglitazone)**
  - MoA: PPAR-γ Agonists, ↑ Insulin Sensitivity in Adipose, Muscle, Liver
  - Side Effects: Fluid Retention/Edema, Heart Failure (Key), Weight Gain, Bone Fractures, Bladder Cancer (Pioglitazone)
  - Contraindications: Heart Failure (NYHA III/IV), Active Bladder Cancer (Pioglitazone), Severe Hepatic Impairment
  - Pearls: Slow onset/offset, No Hypoglycemia risk

### Incretin-Based Therapies
- **DPP-4 Inhibitors (Gliptins) (Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin)**
  - MoA: Inhibit DPP-4, ↑ Endogenous GLP-1 & GIP
  - Side Effects: Pancreatitis (Rare), Joint Pain (Arthralgia), HF (Saxagliptin), Renal adjustment (except Linagliptin)
  - Pearls: Weight Neutral, Low Hypoglycemia Risk

- **GLP-1 Receptor Agonists (Tides - Oral Semaglutide)** (Often discussed with OHAs)
  - MoA: GLP-1 Mimetic
  - Side Effects: GI Upset (Nausea, Vomiting), Pancreatitis, Medullary Thyroid Cancer (Key, avoid in MEN2/FMTC)
  - Pearls: Weight Loss (Key), Cardiovascular Benefit (Key for Liraglutide, Semaglutide)

### Alpha-Glucosidase Inhibitors
- **Acarbose, Miglitol**
  - MoA: Inhibit intestinal alpha-glucosidase, delay carbohydrate absorption
  - Side Effects: GI Upset (Flatulence, Diarrhea - Key)
  - Pearls: Must take with meals, Target post-prandial glucose, Low Hypoglycemia Risk (unless combined)

### SGLT-2 Inhibitors
- **SGLT-2 Inhibitors (Flozins) (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin)**
  - MoA: Inhibit SGLT-2 in kidney, ↑ Glucose excretion in urine
  - Side Effects: Genitourinary Infections (Key), Dehydration/Hypotension, Euglycemic DKA (Key), Amputations (Canagliflozin), Fournier's Gangrene
  - Contraindications: Severe Renal Impairment (eGFR <30-45 depending on agent)
  - Pearls: Weight Loss (Key), BP Reduction, **CV Benefit** (Key - HFrEF, ASCVD), **Renal Benefit** (Key - CKD in DM)

## INICET Buzzwords
- **Lactic Acidosis** (Metformin)
- **Hypoglycemia** (Sulfonylureas, Meglitinides, Insulin)
- **Heart Failure** (TZDs, Saxagliptin)
- **Genitourinary Infections** (SGLT-2 Inhibitors)
- **Euglycemic DKA** (SGLT-2 Inhibitors)
- **Medullary Thyroid Cancer** (GLP-1 RAs)
- **Weight Loss** (SGLT-2 Inhibitors, GLP-1 RAs, Metformin)
- **Cardiovascular Benefit** (SGLT-2 Inhibitors, GLP-1 RAs, Metformin)
- **Renal Benefit** (SGLT-2 Inhibitors, Metformin)
- **B12 Deficiency** (Metformin)
- **Fluid Retention** (TZDs)
- **Flatulence** (Alpha-Glucosidase Inhibitors)
- **Pancreatitis** (DPP-4 Inhibitors, GLP-1 RAs)
- **Arthralgia** (DPP-4 Inhibitors)
- **eGFR** (Crucial for Metformin, SGLT-2i, many others)
- **Post-prandial Glucose** (Meglitinides, Alpha-Glucosidase Inhibitors)
- **PPAR-γ** (TZDs)
- **DPP-4** (Gliptins)
- **GLP-1** (DPP-4i, GLP-1 RAs)
- **SGLT-2** (Flozins)
